The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The products will be manufactured in Goa India and marketed & distributed in Australian markets
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Subscribe To Our Newsletter & Stay Updated